Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02187198 · ClinicalTrials.gov registry record · Phase 3
Buprenorphine Treatment for Opioid Dependence
A Phase 3 study of Opioid Dependence, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT02187198: Completed Phase 3 study of Opioid Dependence, sponsored by Yale University.
NCT02187198 is a Phase 3 study of Opioid Dependence that has completed, run by Yale University. The registered enrollment target is 9 participants, below the 158-participant average among 29 other Opioid Dependence trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02187198, a Phase 3 study of Opioid Dependence, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
Buprenorphine/naloxone (BUP/NLX) treatment is effective for the treatment of prescription opioid dependence, previous studies have not determined the optimum dose of BUP/NLX for this patient population. The goal of this study is to determine if there are differences in clinical efficacy of BUP/NLX tablet in low dose range (less than or equal to 8/2mg) vs. high dose range (greater than or equal to 16, range 16-24mg). The main outcomes of interest will be treatment retention, use of opioids, and the use of other drugs of abuse.
Primary Outcome
Will be used to document opioid use, a urine toxicology screening will be completed weekly during study participation (12 week study)
Conditions Studied
Interventions
- DRUG Buprenorphine
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System - West Haven Campus - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-03 |
| Est. Completion | 2023-01-01 |
| Phase | Phase 3 |
What the finished NCT02187198 record still lists
NCT02187198 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 158-participant average among 29 other Opioid Dependence trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Opioid Dependence appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine is the first listed.
NCT02187198 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02187198 about?
NCT02187198 is a clinical study titled "Buprenorphine Treatment for Opioid Dependence". Buprenorphine/naloxone (BUP/NLX) treatment is effective for the treatment of prescription opioid dependence, previous studies have not determined the optimum dose of BUP/NLX for this patient population. The goal of this study is to determine if there are differences in clinical efficacy of BUP/NLX t...
What is the current status of trial NCT02187198?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2015-03. Estimated completion is 2023-01-01.
What conditions does trial NCT02187198 study?
This clinical trial studies the following conditions: Opioid Dependence.
What interventions are being tested in trial NCT02187198?
The interventions under investigation include: Buprenorphine (DRUG).
Who is sponsoring clinical trial NCT02187198?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02187198 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02187198's enrollment target sits among peer trials
9 29th of 29 the lowest of 29 other Opioid Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Facilitating Rapid Naltrexone Initiation
ACTIVE NOT RECRUITING · Phase 3
-
Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine
COMPLETED · Phase 3
-
Neuromodulation and Cognitive Training in Opioid Use Disorder
RECRUITING · NA
-
Intervening With Opioid-Dependent MothersMothers and Infants
RECRUITING · NA
-
fMRI and Opioid Abstinence
RECRUITING
-
Better Options for Chronic Cancer Pain
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia